Type 2 diabetes significantly increased the risk of mortality and heart failure hospitalization in HFpEF patients (HR 1.72), while among diabetic patients, intensive glycemic control (HbA1C < 7%) was associated with worse prognosis (HR 2.07).
Cohort (n=183)
No
Does type 2 diabetes and intensive glycemic control (HbA1C <7%) affect the risk of all-cause mortality or heart failure hospitalization in patients with HFpEF?
In patients with HFpEF, diabetes is associated with worse outcomes, but intensive glycemic control (HbA1C <7%) in diabetic patients paradoxically predicts higher mortality and HF hospitalization.
Hazard Ratio: 1.72 (95% CI 1.1–2.6)
Tasa de eventos absoluta: 78% vs 54%
valor p: p=0.011
Abstract Background Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous syndrome, with several underlying etiologic and pathophysiologic factors. The presence of diabetes might identify an important phenotype, with implications for therapeutic strategies. While diabetes is associated with worse prognosis in HFpEF, the prognostic impact of glycemic control is yet unknown. Hence, we investigated phenotypic differences between diabetic and non-diabetic HFpEF patients (pts), and the prognostic impact of glycated hemoglobin (HbA1C). Methods We prospectively enrolled 183 pts with HFpEF (78 ± 9 years, 38% men), including 70 (38%) diabetics (type 2 diabetes only). They underwent 2D echocardiography (n = 183), cardiac magnetic resonance (CMR) (n = 150), and were followed for a combined outcome of all-cause mortality and first HF hospitalization. The prognostic impact of diabetes and glycemic control were determined with Cox proportional hazard models, and illustrated by adjusted Kaplan Meier curves. Results Diabetic HFpEF pts were younger (76 ± 9 vs 80 ± 8 years, p = 0.002), more obese (BMI 31 ± 6 vs 27 ± 6 kg/m 2 , p = 0.001) and suffered more frequently from sleep apnea (18% vs 7%, p = 0.032). Atrial fibrillation, however, was more frequent in non-diabetic pts (69% vs 53%, p = 0.028). Although no echocardiographic difference could be detected, CMR analysis revealed a trend towards higher LV mass (66 ± 18 vs 71 ± 14 g/m 2 , p = 0.07) and higher levels of fibrosis (53% vs 36% of patients had ECV by T1 mapping > 33%, p = 0.05) in diabetic patients. Over 25 ± 12 months, 111 HFpEF pts (63%) reached the combined outcome (24 deaths and 87 HF hospitalizations). Diabetes was a significant predictor of mortality and hospitalization for heart failure (HR: 1.72 1.1–2.6, p = 0.011, adjusted for age, BMI, NYHA class and renal function). In diabetic patients, lower levels of glycated hemoglobin (HbA1C < 7%) were associated with worse prognosis (HR: 2.07 1.1–4.0, p = 0.028 adjusted for age, BMI, hemoglobin and NT-proBNP levels). Conclusion Our study highlights phenotypic features characterizing diabetic patients with HFpEF. Notably, they are younger and more obese than their non-diabetic counterpart, but suffer less from atrial fibrillation. Although diabetes is a predictor of poor outcome in HFpEF, intensive glycemic control (HbA1C < 7%) in diabetic patients is associated with worse prognosis.
Lejeune et al. (Fri,) conducted a cohort in Heart failure with preserved ejection fraction (HFpEF) (n=183). Type 2 diabetes vs. Non-diabetic patients was evaluated on Composite of all-cause mortality or hospitalization for heart failure (HR 1.72, 95% CI 1.1-2.6, p=0.011). Type 2 diabetes significantly increased the risk of mortality and heart failure hospitalization in HFpEF patients (HR 1.72), while among diabetic patients, intensive glycemic control (HbA1C < 7%) was associated with worse prognosis (HR 2.07).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: